{"id":71443,"date":"2025-05-14T16:13:35","date_gmt":"2025-05-14T16:13:35","guid":{"rendered":"https:\/\/www.imperialcrs.com\/blog\/?p=71443"},"modified":"2025-09-02T13:58:23","modified_gmt":"2025-09-02T17:58:23","slug":"clinical-trial-diversity-action-plans-6-key-components-for-compliance","status":"publish","type":"post","link":"https:\/\/www.imperialcrs.com\/blog\/business-insights\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\/","title":{"rendered":"Clinical Trial Diversity Action Plans: 6 Key Components for Compliance"},"content":{"rendered":"

Diversity in clinical trials is now mandated by law. While the importance of study diversity has long been emphasized, this marks the first time it has been codified into law under the Food and Drug Omnibus Reform Act of 2022 (FDORA).1 <\/sup>Through diversity action plans, this requirement is designed to increase the inclusion of underrepresented populations in pivotal clinical research.<\/p>\n

Ensuring that clinical trials reflect the diverse populations who will ultimately use a drug or device is not just a scientific imperative; it\u2019s a moral one. Historically, certain racial, ethnic, and age groups have been severely underrepresented in clinical research. This has led to health disparities, mistrust in the system, and medical products that may not work equally well for all patients. A robust Diversity Action Plan (DAP), required in Section 3601 of FDORA,1<\/sup> is a critical step in addressing these gaps.<\/p>\n

In this blog, we explore the six core components of a DAP. We offer examples and suggestions for sponsors and share insights to help you navigate compliance while building more equitable and effective studies.<\/p>\n

Regulatory Context and Industry Guidance<\/h2>\n

Section 3602 of FDORA requires the FDA to issue or update guidance on diversity action plans. The FDA’s most current guidance\u2014released in June 2024\u2014provides sponsors with detailed recommendations on what to include in a DAP and how to align it with trial design and protocol development.2<\/sup><\/p>\n

\n

These plans may help ensure that sponsors are thinking critically and intentionally about the many characteristics of the patient population they aim to treat when designing their clinical study.\u201d<\/em><\/p>\n

\u2014 Dr. Richard Pazdur, Director, FDA Oncology Center of Excellence<\/em>3<\/sup><\/p><\/blockquote>\n<\/div>\n

Though still in draft form, the guidance reflects the FDA\u2019s current thinking and serves as a benchmark for proactive sponsors preparing Phase 3 submissions. The compliance deadline for mandatory submission of DAPs is 180 days after the final FDA DAP guidance is issued.<\/p>\n

In January 2025, Robert F. Kennedy Jr. told U.S. senators during his\u00a0confirmation hearing for the position of U.S. Department of Health and Human Services Secretary, which oversees the FDA, that he would finalize the FDA\u2019s guidance on increasing clinical trial diversity. However, he did not commit to a specific timeline or guidance content.<\/p>\n

What Is a Diversity Action Plan (DAP)?<\/h2>\n

\"Diversity<\/p>\n

A Diversity Action Plan is a formal document submitted to the FDA as part of the regulatory package for most Phase 3 and pivotal clinical trials. It outlines how the sponsor will ensure that clinical trial participants reflect the demographics of the population most likely to use the investigational product. These plans promote the inclusion of historically underrepresented populations based on race, ethnicity, sex, age, geography, and other factors.<\/p>\n

By establishing and executing these plans early in trial design, sponsors fulfill regulatory expectations. And they also improve clinical study integrity and public trust.<\/p>\n

6 Key Components of Diversity Action Plans<\/h2>\n

1. <\/strong>Enrollment Goals<\/h3>\n

Sponsors must set clear, measurable targets for the enrollment of participants from diverse demographic groups\u2014particularly by race, ethnicity, age, and sex.<\/p>\n

2. Justification of Goals<\/h3>\n

These enrollment goals must be supported by relevant scientific, demographic, or public health data about the disease condition and its prevalence.<\/p>\n

3. Recruitment Strategies<\/h3>\n

DAPs must outline how sponsors will reach and engage diverse populations. This often requires tailored outreach and community engagement along with diversity training for study personnel.<\/p>\n

4. Retention Strategies<\/h3>\n

Enrollment is only half the equation. Retaining participants from underrepresented populations is equally essential to trial integrity.<\/p>\n

5. Monitoring and Reporting<\/h3>\n

The plan should explain how sponsors will track their progress toward enrollment targets. This should include an expectation to adjust mid-trial tactics if goals are not being met.<\/p>\n

6. Site Selection Considerations<\/h3>\n

ClinicalTrials.gov is a valuable resource. It allows sponsors to review enrollment patterns from past trials, identify locations where diverse populations have been successfully recruited, and benchmark study designs.4<\/sup><\/p>\n

Final Thoughts<\/strong><\/h2>\n

The implementation of Diversity Action Plans marks a watershed moment in clinical research. By elevating diversity from an ethical aspiration to a regulatory requirement, the FDA is reinforcing the need for inclusive science<\/strong> that reflects real-world populations.<\/p>\n

Sponsors who take this seriously will do far more than just check a box. They will build more robust data sets, reduce bias, and increase credibility with regulators. Most importantly, they will develop therapies that serve all patients<\/strong>, not just a subset.<\/p>\n

How Imperial Supports <\/strong>Implementation of <\/strong>Diversity Action Plans\u00a0<\/strong><\/h2>\n

While sponsors are responsible for developing and submitting Diversity Action Plans, Imperial Clinical Research Services<\/strong> offers operational support to help carry out the goals outlined in those plans. We don\u2019t craft or author DAPs. But we do support the practical implementation of outreach, communication, and logistics strategies that help make diversity targets achievable.<\/p>\n

Patient-Facing Materials<\/h3>\n

We develop and distribute print and digital culturally diverse and multilingual patient materials. These include consent form overview presentations, visit instructions, and engagement tools to help improve understanding, enrollment, and retention.<\/p>\n

Translation and Localization Services<\/h3>\n

Imperial provides certified translation and cultural adaptation services for study documents and materials. These support participants whose first language isn\u2019t English and reduce barriers to access.<\/p>\n

Global Logistics and Material Distribution<\/h3>\n

We deliver clinical trial materials\u2014including patient kits and site supplies\u2014to a wide network of trial locations, including geographically diverse or underserved areas often central to DAP recruitment goals.<\/p>\n

Custom Kitting Services<\/h3>\n

Our team builds patient and site kits that are tailored to the population, including translated components or culturally relevant instructions that align with DAP implementation.<\/p>\n

Retention and Engagement Tools<\/h3>\n

We offer materials that support participant engagement and continuity\u2014appointment reminders, diaries, or educational content\u2014to help reduce dropout rates, especially in underrepresented communities.<\/p>\n

Imperial\u2019s flexible, experienced infrastructure enables sponsors to carry out the logistics and communication strategies necessary for DAP success<\/strong>, all while supporting regulatory compliance and trial inclusivity. Contact us<\/a> for more information on how we can help with your clinical trial.<\/p>\n

This blog is part of a 2-part series. Check out: The Upcoming FDA Clinical Trial Diversity Mandate: What You Need to Know.<\/a><\/p>\n

References<\/strong><\/h2>\n
    \n
  1. U.S. Congress. Food and Drug Omnibus Reform Act of 2022<\/em>. #2697 New FDAR white paper- The Food and Drug Omnibus Reform Act of 2022 (FDORA)_B<\/a><\/li>\n
  2. U.S. Food & Drug Administration. Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies (Draft Guidance, June 2024)<\/em>. Download Draft Guidance Here (Attachments – Center of the Page)<\/a><\/li>\n
  3. Reuters. US FDA Issues Guidance for Drugmakers on Diversity in Clinical Studies<\/em>.
    \n    https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/us-fda-issues-guidance-drugmakers-diversity-studies-2024-06-26<\/a><\/li>\n
  4. ClinicalTrials.gov. Searchable Trial Demographics Database<\/em>.
    \n    https:\/\/www.clinicaltrials.gov<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Diversity in clinical trials is now mandated by law. While the importance of study diversity has long been emphasized, this marks the first time it has been codified into law under the Food and Drug Omnibus Reform Act of 2022 (FDORA).1 Through diversity action plans,…<\/p>\n","protected":false},"author":36,"featured_media":71464,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[22,365,379,35],"tags":[83,889,465,1830,575,50,891,898,887,894,2027,455,1835],"class_list":["post-71443","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-insights","category-clinical-trial-writing-and-design","category-patient-engagement","category-patient-recruitment-and-retention","tag-clinical-research","tag-clinical-research-diversity-trends","tag-clinical-research-strategies","tag-clinical-trial-diversity","tag-clinical-trial-planning","tag-clinical-trials","tag-diversity-and-inclusion-in-clinical-trials","tag-diversity-challenges-in-medical-research","tag-diversity-in-clinical-trials","tag-diversity-initiatives-in-research","tag-fda-clinical-trial-diversity","tag-regulatory-compliance","tag-representing-diversity-in-research"],"acf":[],"yoast_head":"\nClinical Trial Diversity Action Plans: 6 Key Components for Compliance - Imperial Clinical Research Services Blog<\/title>\n<meta name=\"description\" content=\"In this blog, discover the essential components of federally required diversity action plans for clinical trials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.imperialcrs.com\/blog\/business-insights\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinical Trial Diversity Action Plans: 6 Key Components for Compliance - Imperial Clinical Research Services Blog\" \/>\n<meta property=\"og:description\" content=\"In this blog, discover the essential components of federally required diversity action plans for clinical trials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.imperialcrs.com\/blog\/business-insights\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\/\" \/>\n<meta property=\"og:site_name\" content=\"Imperial Clinical Research Services Blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-14T16:13:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-02T17:58:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2025\/05\/Clinical-trial-diversity-action-plans.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Vaughn X. Anthony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Vaughn X. Anthony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/business-insights\\\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/business-insights\\\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\\\/\"},\"author\":{\"name\":\"Vaughn X. Anthony\",\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/#\\\/schema\\\/person\\\/a7e2027302fa6fa5c8848b7465b59cb5\"},\"headline\":\"Clinical Trial Diversity Action Plans: 6 Key Components for Compliance\",\"datePublished\":\"2025-05-14T16:13:35+00:00\",\"dateModified\":\"2025-09-02T17:58:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/business-insights\\\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\\\/\"},\"wordCount\":1085,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/business-insights\\\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Clinical-trial-diversity-action-plans.jpg\",\"keywords\":[\"Clinical Research\",\"Clinical Research Diversity Trends\",\"Clinical Research Strategies\",\"Clinical Trial Diversity\",\"Clinical Trial Planning\",\"Clinical Trials\",\"Diversity and Inclusion in Clinical Trials\",\"Diversity Challenges in Medical Research\",\"Diversity in Clinical Trials\",\"Diversity Initiatives in Research\",\"FDA clinical trial diversity\",\"Regulatory compliance\",\"Representing Diversity in Research\"],\"articleSection\":[\"Business Insights\",\"Clinical Trial Writing and Design\",\"Patient Engagement\",\"Patient Recruitment and Retention\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/business-insights\\\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/business-insights\\\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\\\/\",\"url\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/business-insights\\\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\\\/\",\"name\":\"Clinical Trial Diversity Action Plans: 6 Key Components for Compliance - Imperial Clinical Research Services Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/business-insights\\\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/business-insights\\\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Clinical-trial-diversity-action-plans.jpg\",\"datePublished\":\"2025-05-14T16:13:35+00:00\",\"dateModified\":\"2025-09-02T17:58:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/#\\\/schema\\\/person\\\/a7e2027302fa6fa5c8848b7465b59cb5\"},\"description\":\"In this blog, discover the essential components of federally required diversity action plans for clinical trials.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/business-insights\\\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/business-insights\\\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/business-insights\\\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Clinical-trial-diversity-action-plans.jpg\",\"contentUrl\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Clinical-trial-diversity-action-plans.jpg\",\"width\":1200,\"height\":800,\"caption\":\"Clinical trial diversity action plans\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/business-insights\\\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clinical Trial Diversity Action Plans: 6 Key Components for Compliance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/\",\"name\":\"Imperial Clinical Research Services Blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/#\\\/schema\\\/person\\\/a7e2027302fa6fa5c8848b7465b59cb5\",\"name\":\"Vaughn X. Anthony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/abecf43c291b32a2850b13cac223471eda00a906a2b757538f8a9f22249c1fb2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/abecf43c291b32a2850b13cac223471eda00a906a2b757538f8a9f22249c1fb2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/abecf43c291b32a2850b13cac223471eda00a906a2b757538f8a9f22249c1fb2?s=96&d=mm&r=g\",\"caption\":\"Vaughn X. Anthony\"},\"description\":\"Vaughn is the Director of Creative Services and Marketing at Imperial Clinical Research Services, where he leads the company\u2019s in-house creative team of award-winning writers and graphic designers in delivering strategic, patient-centric solutions for global clinical trials. With deep expertise in the industry, Vaughn collaborates closely with sponsors, CROs, and site networks to craft creative assets that are both regulatory-compliant and culturally resonant. His leadership ensures that every campaign, whether for patient recruitment, retention, or site support, is grounded in empathy, clarity, and scientific accuracy. Vaughn\u2019s ability to translate complex clinical concepts into accessible, compelling communications has helped drive enrollment success across a wide range of therapeutic areas. Recognized for his contributions to the life sciences industry, Vaughn was named one of PharmaVoice\u2019s 100 Most Inspiring People in Life Sciences.\",\"url\":\"https:\\\/\\\/www.imperialcrs.com\\\/blog\\\/author\\\/vanthony\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clinical Trial Diversity Action Plans: 6 Key Components for Compliance - Imperial Clinical Research Services Blog","description":"In this blog, discover the essential components of federally required diversity action plans for clinical trials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.imperialcrs.com\/blog\/business-insights\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\/","og_locale":"en_US","og_type":"article","og_title":"Clinical Trial Diversity Action Plans: 6 Key Components for Compliance - Imperial Clinical Research Services Blog","og_description":"In this blog, discover the essential components of federally required diversity action plans for clinical trials.","og_url":"https:\/\/www.imperialcrs.com\/blog\/business-insights\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\/","og_site_name":"Imperial Clinical Research Services Blog","article_published_time":"2025-05-14T16:13:35+00:00","article_modified_time":"2025-09-02T17:58:23+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2025\/05\/Clinical-trial-diversity-action-plans.jpg","type":"image\/jpeg"}],"author":"Vaughn X. Anthony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Vaughn X. Anthony","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.imperialcrs.com\/blog\/business-insights\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\/#article","isPartOf":{"@id":"https:\/\/www.imperialcrs.com\/blog\/business-insights\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\/"},"author":{"name":"Vaughn X. Anthony","@id":"https:\/\/www.imperialcrs.com\/blog\/#\/schema\/person\/a7e2027302fa6fa5c8848b7465b59cb5"},"headline":"Clinical Trial Diversity Action Plans: 6 Key Components for Compliance","datePublished":"2025-05-14T16:13:35+00:00","dateModified":"2025-09-02T17:58:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.imperialcrs.com\/blog\/business-insights\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\/"},"wordCount":1085,"commentCount":0,"image":{"@id":"https:\/\/www.imperialcrs.com\/blog\/business-insights\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2025\/05\/Clinical-trial-diversity-action-plans.jpg","keywords":["Clinical Research","Clinical Research Diversity Trends","Clinical Research Strategies","Clinical Trial Diversity","Clinical Trial Planning","Clinical Trials","Diversity and Inclusion in Clinical Trials","Diversity Challenges in Medical Research","Diversity in Clinical Trials","Diversity Initiatives in Research","FDA clinical trial diversity","Regulatory compliance","Representing Diversity in Research"],"articleSection":["Business Insights","Clinical Trial Writing and Design","Patient Engagement","Patient Recruitment and Retention"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.imperialcrs.com\/blog\/business-insights\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.imperialcrs.com\/blog\/business-insights\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\/","url":"https:\/\/www.imperialcrs.com\/blog\/business-insights\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\/","name":"Clinical Trial Diversity Action Plans: 6 Key Components for Compliance - Imperial Clinical Research Services Blog","isPartOf":{"@id":"https:\/\/www.imperialcrs.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.imperialcrs.com\/blog\/business-insights\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\/#primaryimage"},"image":{"@id":"https:\/\/www.imperialcrs.com\/blog\/business-insights\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2025\/05\/Clinical-trial-diversity-action-plans.jpg","datePublished":"2025-05-14T16:13:35+00:00","dateModified":"2025-09-02T17:58:23+00:00","author":{"@id":"https:\/\/www.imperialcrs.com\/blog\/#\/schema\/person\/a7e2027302fa6fa5c8848b7465b59cb5"},"description":"In this blog, discover the essential components of federally required diversity action plans for clinical trials.","breadcrumb":{"@id":"https:\/\/www.imperialcrs.com\/blog\/business-insights\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.imperialcrs.com\/blog\/business-insights\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.imperialcrs.com\/blog\/business-insights\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\/#primaryimage","url":"https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2025\/05\/Clinical-trial-diversity-action-plans.jpg","contentUrl":"https:\/\/www.imperialcrs.com\/blog\/wp-content\/uploads\/2025\/05\/Clinical-trial-diversity-action-plans.jpg","width":1200,"height":800,"caption":"Clinical trial diversity action plans"},{"@type":"BreadcrumbList","@id":"https:\/\/www.imperialcrs.com\/blog\/business-insights\/clinical-trial-diversity-action-plans-6-key-components-for-compliance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.imperialcrs.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Clinical Trial Diversity Action Plans: 6 Key Components for Compliance"}]},{"@type":"WebSite","@id":"https:\/\/www.imperialcrs.com\/blog\/#website","url":"https:\/\/www.imperialcrs.com\/blog\/","name":"Imperial Clinical Research Services Blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.imperialcrs.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.imperialcrs.com\/blog\/#\/schema\/person\/a7e2027302fa6fa5c8848b7465b59cb5","name":"Vaughn X. Anthony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/abecf43c291b32a2850b13cac223471eda00a906a2b757538f8a9f22249c1fb2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/abecf43c291b32a2850b13cac223471eda00a906a2b757538f8a9f22249c1fb2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/abecf43c291b32a2850b13cac223471eda00a906a2b757538f8a9f22249c1fb2?s=96&d=mm&r=g","caption":"Vaughn X. Anthony"},"description":"Vaughn is the Director of Creative Services and Marketing at Imperial Clinical Research Services, where he leads the company\u2019s in-house creative team of award-winning writers and graphic designers in delivering strategic, patient-centric solutions for global clinical trials. With deep expertise in the industry, Vaughn collaborates closely with sponsors, CROs, and site networks to craft creative assets that are both regulatory-compliant and culturally resonant. His leadership ensures that every campaign, whether for patient recruitment, retention, or site support, is grounded in empathy, clarity, and scientific accuracy. Vaughn\u2019s ability to translate complex clinical concepts into accessible, compelling communications has helped drive enrollment success across a wide range of therapeutic areas. Recognized for his contributions to the life sciences industry, Vaughn was named one of PharmaVoice\u2019s 100 Most Inspiring People in Life Sciences.","url":"https:\/\/www.imperialcrs.com\/blog\/author\/vanthony\/"}]}},"_links":{"self":[{"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/posts\/71443","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/comments?post=71443"}],"version-history":[{"count":21,"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/posts\/71443\/revisions"}],"predecessor-version":[{"id":71740,"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/posts\/71443\/revisions\/71740"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/media\/71464"}],"wp:attachment":[{"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/media?parent=71443"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/categories?post=71443"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.imperialcrs.com\/blog\/wp-json\/wp\/v2\/tags?post=71443"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}